A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Mutant p53 Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to Mortaparib, a Multimodal Small Molecule Inhibitor. | LitMetric

AI Article Synopsis

  • The study identified Mortaparib as a potential drug that inhibits the interaction between mortalin and p53 in breast cancer cells after extensive drug screenings.
  • Mortaparib was found to disrupt the mortalin-p53 interaction in MCF-7 and T47D cells, leading to different outcomes: MCF-7 cells showed increased p53 activity while T47D cells demonstrated a hyperactivation of PARP1 without inducing apoptosis.
  • The research indicates that cancer cells with high levels of AIF-mortalin complexes may not respond to Mortaparib, highlighting its complex anticancer effects and the need for further research.

Article Abstract

We previously performed a drug screening to identify a potential inhibitor of mortalin-p53 interaction. In four rounds of screenings based on the shift in mortalin immunostaining pattern from perinuclear to pan-cytoplasmic and nuclear enrichment of p53, we had identified Mortaparib (4-[(1E)-2-(2-phenylindol-3-yl)-1-azavinyl]-1,2,4-triazole) as a novel synthetic small molecule. In order to validate its activity and mechanism of action, we recruited Luminal-A breast cancer cells, MCF-7 (p53) and T47D (p53) and performed extensive biochemical and immunocytochemical analyses. Molecular analyses revealed that Mortaparib is capable of abrogating mortalin-p53 interaction in both MCF-7 and T47D cells. Intriguingly, upregulation of transcriptional activation function of p53 (as marked by upregulation of the p53 effector gene--responsible for cell cycle arrest and apoptosis) was recorded only in Mortaparib-treated MCF-7 cells. On the other hand, Mortaparib-treated T47D cells exhibited hyperactivation of PARP1 (accumulation of PAR polymer and decrease in ATP levels) as a possible non-p53 tumor suppression program. However, these cells did not show full signs of either apoptosis or PAR-Thanatos. Molecular analyses attributed such a response to the inability of Mortaparib to disrupt the AIF-mortalin complexes; hence, AIF did not translocate to the nucleus to induce chromatinolysis and DNA degradation. These data suggested that the cancer cells possessing enriched levels of such complexes may not respond to Mortaparib. Taken together, we report the multimodal anticancer potential of Mortaparib that warrants further attention in laboratory and clinical studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234533PMC
http://dx.doi.org/10.3390/cancers13123043DOI Listing

Publication Analysis

Top Keywords

cancer cells
12
luminal-a breast
8
breast cancer
8
cell cycle
8
cycle arrest
8
small molecule
8
mortalin-p53 interaction
8
molecular analyses
8
t47d cells
8
cells
7

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!